Innovent Biologics
2000 Alameda de las Pulgas, suite 120
San Mateo
CA
94403
United States
Website: https://www.innoventbio.com/
223 articles about Innovent Biologics
-
Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO)
4/16/2024
Innovent Biologics, Inc. announces the appointment of Dr. Nageatte Ibrahim, a world-famous Oncology Clinical Development Leader in the Pharmaceutical Industry, as the Oncology CMO.
-
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status
4/2/2024
Innovent Biologics, Inc. and HUTCHMED Limited jointly announce that the New Drug Application for the combination of sintilimab and fruquintinib for the treatment of patients with advanced endometrial cancer with pMMR[1] or non-MSI-H[2] tumors that have failed prior systemic therapy but are not candidates for curative surgery or radiation has been accepted and granted priority review by the China National Medical Products Administration.
-
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
4/2/2024
HUTCHMED Limited and Innovent Biologics, Inc. jointly announce that the New Drug Application for the combination of fruquintinib and sintilimab for the treatment of patients with advanced endometrial cancer with pMMR1 or non-MSI-H2 tumors that have failed prior systemic therapy but are not candidates for curative surgery or radiation has been accepted and granted priority review by the China National Medical Products Administration.
-
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
3/27/2024
Innovent Biologics, Inc. announces that the first participant has been successfully dosed with IBI310 in combination with sintilimab in a randomized, controlled, multicenter Phase 3 clinical trial, for resectable MSI-H/dMMR[1] colon cancer neoadjuvant therapy.
-
Innovent Announces 2023 Annual Results and Business Updates
3/20/2024
Innovent Biologics, Inc. announces its 2023 annual results and major business updates.
-
Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD)
3/19/2024
Innovent Biologics, Inc. announced that the primary endpoint has been met in the second Phase 2 clinical study of efdamrofusp alfa high-dose, a recombinant human VEGFR-Fc-Human CR1 fusion protein injection, in Chinese subjects with neovascular age-related macular degeneration.
-
Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting
3/12/2024
Innovent Biologics, Inc. announces that preclinical data on multiple novel bispecific antibodies as well as antibody-drug-conjugates from its oncology pipeline will be presented at the American Association for Cancer Research Annual Meeting 2024.
-
The Chinese biopharma company will be closing its U.S. headquarters and wet lab in the D.C. suburbs, according to scientists who recently lost their jobs.
-
Innovent released the results of two clinical studies of IBI311 (an anti-IGF-1R monoclonal antibody) in oral presentations at the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024
3/7/2024
Innovent Biologics, Inc. announced that the results of two clinical studies of IBI311,a Phase I trial in healthy subjects and a Phase II trial in patients with thyroid eye disease, in the form of oral presentation at the 39th Asia Pacific Academy of Ophthalmology Congress and the 21st International Congress of Endocrinology, respectively.
-
Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
3/5/2024
Innovent Biologics, Inc. and AnHeart Therapeutics announce that the Center for Drug Evaluation of China's National Medical Products Administration has accepted a second New Drug Application for taletrectinib adipate capsule, a next-generation ROS1 tyrosine kinase inhibitor.
-
AnHeart Therapeutics and Innovent Announce China’s NMPA has Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
3/5/2024
AnHeart Therapeutics and Innovent Biologics, Inc. announced that the Center for Drug Evaluation of China’s National Medical Products Administration has accepted a second New Drug Application for taletrectinib, a next-generation ROS1 tyrosine kinase inhibitor.
-
Innovent Announces First Participant Dosed in a Phase I Study of IBI3002 (an anti-IL-4Rα/TSLP bispecific antibody) in Australia
2/29/2024
Innovent Biologics, Inc. (Innovent) (HKEX: 01801) announces that the first participant has been dosed in Australia in a first-in-human (FIH) phase 1 clinical trial of IBI3002, a global first-in-class bispecific antibody targeting Interleukin 4 receptor α (IL-4Rα) and thymic stromal lymphopoietin (TSLP).
-
Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA
2/19/2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801) today announced that the primary endpoint has been achieved in the Phase 3 registrational study (RESTORE-1) of IBI311, a recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody in Chinese subjects with Thyroid Eye Disease (TED).
-
Innovent's First New Drug Application of Mazdutide for Chronic Weight Management has been Accepted by the NMPA of China
2/7/2024
Innovent Biologics, Inc. announces that the New Drug Application for mazdutide, a glucagon-like peptide-1 receptor and glucagon receptor dual agonist, has been accepted by the Center for Drug Evaluation of the National Medical Products Administration of China, for chronic weight management in adults with obesity or overweight.
-
Innovent Announces Retirement of CFO and Appointment of New CFO
2/5/2024
Innovent Biologics, Inc. announced that Mr. Ronald Hao Xi Ede will retire from his position as the chief financial officer after a seven-year distinguished career with the Company.
-
Innovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA
1/9/2024
Innovent Biologics, Inc. (Innovent) (HKEX: 01801) announces that the first Phase 3 clinical trial of mazdutide (Innovent R&D code: IBI362), a glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese adults with overweight or obesity (GLORY-1) met the primary endpoints and all key secondary endpoints.
-
Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity
1/2/2024
Innovent Biologics, Inc. announces that the first participant has been successfully dosed in a Phase 3 clinical trial of higher dose 9 mg mazdutide, a glucagon-like peptide 1 receptor and glucagon receptor dual agonist, in Chinese adults with obesity.
-
Innovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China
12/28/2023
Innovent Biologics, Inc. and Xuanzhu Biopharma, announce that they entered into a clinical trial collaboration and supply agreement for the combination therapies of sintilimab injection with KM-501, a novel HER-2 bispecific ADC, as potential treatment options for advanced solid tumors in China.
-
Innovent and SanegeneBio Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of Hypertension
12/27/2023
Innovent Biologics, Inc. and Sanegene Bio USA Inc. announce that they have entered into a collaboration agreement to co-develop SGB-3908, an siRNA drug candidate targeting angiotensinogen for the treatment of hypertension.
-
AnHeart Therapeutics and Innovent Announce China’s NMPA Has Granted Taletrectinib (ROS1 Inhibitor) Priority Review Designation
12/18/2023
AnHeart Therapeutics (“AnHeart”) and Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, today announced the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted Priority Review Designation for the New Drug Application (NDA) of taletrectinib.